AUTHORS
Dimitra Karagkouni, PhD, Giulia Cheloni, PhD2, Shuoshuo Wang3, Isabella Saldarriaga4, Hazal Toros5, Zoe Sokol6, Yuling Ma7, Xanthi-Lida Katopodi8, Sheethal Nagalakshmi9, Jessica Liegel, MD10, Steven Mason Foltz, PhD11, George Mulligan, PhD12, Hearn Cho13, David J Chung, MD, PhD14, Nina Shah15, Natalie S Callander, MD16, Binod Dhakal, MD, MS17, Nikhil Munshi, MD18, Kenneth Anderson, MD19, Yvonne Efebera, MD, MPH20, Hillard M Lazarus, MD21, Ehsan Malek22, Ajay K Nooka, MD, MPH23, Krina Patel Jr, MD, MSc24, Aaron Rapoport, MD25, Ned K. Waller, MD,PhD26, Marcelo C Pasquini27, Jacalyn Rosenblatt, MD28, Ioannis Vlachos, PhD29, David E. Avigan, MD30
AFFILIATIONS
1 Harvard Medical School, Beth Israel Deaconess Medical Center, Broad Institute of MIT and Harvard, Boston, United States
2 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
3 Harvard Medical School, Beth Israel Deaconess Medical Center, Broad Institute of MIT and Harvard, Boston, United States
4 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
5 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
6 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
7 Harvard Medical School, Beth Israel Deaconess Medical Center, Broad Institute of MIT and Harvard, Boston, United States
8 Harvard Medical School, Beth Israel Deaconess Medical Center, Department of Pathology, United States
9 Harvard Medical School, Beth Israel Deaconess Medical Center, Broad Institute of MIT and Harvard, Boston, United States
10 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
11 Multiple Myeloma Research Foundation, Norwalk, United States
12 Multiple Myeloma Research Foundation, Norwalk, United States
13 Multiple Myeloma Research Foundation, Norwalk, United States
14 Northwell Health Cancer Institute, New York, United States
15 University of California, San Francisco, United States
16 University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, United States
17 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
18 Dana-Farber Cancer Institute, Boston, United States
19 Dana-Farber Cancer Institute, Boston, United States
20 OhioHealth, Columbus, Ohio, United States
21 Case Western Reserve University, Cleveland, United States
22 Case Western Reserve University, Cleveland, United States
23 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 University of Maryland School of Medicine, Baltimore, Maryland, United States
26 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
27 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
28 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
29 Harvard Medical School, Beth Israel Deaconess Medical Center, Broad Institute of MIT and Harvard, Boston, United States
30 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States
ABSTRACT
Background: We have developed a personalized multiple myeloma (MM) vaccine by fusing patient-derived MM cells with autologous dendritic cells (DCs), enabling presentation of shared and patient-specific tumor antigens. In the multicenter CTN 1401 trial, more than 200 patients undergoing autologous HCT were randomized to DC/MM fusion vaccination plus lenalidomide (Len) maintenance or Len alone. Vaccination was feasible, well tolerated, and associated with expansion of MM-reactive effector cells and T-cell clonotypes. Here, we integrated single-cell (sc) immune profiling, antigen discovery, and dextramer-based antigen mapping to correlate T cell clonotypic dynamics with clinical response and define the specificity, clonal evolution, differentiation, and clinical relevance of treatment-associated T cell responses. This approach enabled the pairing of expanded T cell clonotypes with tumor-associated antigens, including cryptic antigens encoded outside the conventionally annotated proteome.
Methods: Longitudinal sc gene expression and paired TCR sequencing were performed on 160 paired bone marrow (BM) and peripheral blood (PB) samples from 40 CTN 1401 patients. Candidate antigens were identified from MM samples by whole-exome sequencing, bulk RNA-seq, ribosome profiling, and machine-learning epitope prioritization. These included mutated neoantigens and cryptic peptides derived from upstream ORFs (uORFs), downstream ORFs (dORFs), and retroelements, including endogenous retroviral elements (ERVs). Antigen-specific T cells were identified by DNA-barcoded dCODE MHC-I Dextramer staining, followed by sc gene-expression, TCR, and barcode profiling. Candidate cryptic antigens were independently evaluated in approximately 250 HLA-A*02:01+ MMRF CoMMpass patients.
Results: sCR/CR and VGPR were associated with activation and clonal expansion of effector-memory T cell clonotypes. Highly expanded clonotypes showed substantial BM-PB sharing: more than half of highly expanded BM clonotypes were detectable in PB at baseline, increasing to 64% at pre-cycle 9 of Len, ~30% of expanded PB clonotypes were detected in BM. BM-PB TCR sharing was greater in sCR/CR, linking recirculation of tumor-associated clonotypes to deeper remission.
Across BM and PB dCODE analyses in 5 HLA-A*02:01+ patients, we profiled 57,747 CD8 T cells with matched state, TCR, and peptide specificity. We identified ~1,000 antigen:TCR pairs spanning 53 peptides, of which ~30% showed clonal expansion (≥2 cells sharing the same TCR). In post-HCT PB samples from patients receiving Len plus vaccination, 152 antigen-specific TCR clonotypes expanded compared to baseline: 138 recognized cryptic dORF-, uORF-, or retroelement-derived peptides and 14 recognized mutated neoantigens. The most prominent treatment-induced responses targeted cryptic peptides derived from a BCMA uORF and ERV1, with antigen-specific clonotypes absent or rare at baseline but expanding markedly post-treatment, including a dominant ERV1-reactive clonotype that increased more than 300-fold. Multiple independent clonotypes converged on the same cryptic peptides (up to 14 distinct TCRs per antigen), consistent with robust antigen-driven T-cell responses.
Pseudotime analysis showed that cells carrying the same antigen-specific TCR spanned a continuous trajectory from early activated states through effector-memory to highly cytotoxic and terminally differentiated states, with the greatest expansion in highly cytotoxic effectors. In contrast, clonotypes recognizing 3 viral control peptides from CMV, EBV, and influenza were broadly distributed across differentiation states, and showed limited post-treatment expansion, consistent with predominantly pre-existing responses.
More than 10 cryptic antigens recognized by expanded T cell clonotypes were recurrently expressed in baseline BM from more than 150 HLA-A*02:01+ CoMMpass patients.
Conclusion: Deep clinical response after HCT in MM is associated with expansion and BM-PB sharing of effector clonotypes. Integrated antigen discovery and sc dCODE profiling identified post-treatment-expanded T cell clones targeting cryptic uORF-, dORF-, and retroelement-derived antigens and resolved their differentiation toward highly cytotoxic and terminal effector states. These findings support coordinated vaccine-associated expansion and differentiation of tumor-reactive T cells and nominate cryptic antigens as shared targets for next-generation MM immunotherapies, including mRNA vaccines.
DISCLOSURES
Dimitra Karagkouni, PhD: No relevant conflicts of interest to declare.